A new post-PKS modification process in the carbamoyltransferase gene inactivation strain of Streptomyces hygroscopicus 17997

被引:10
作者
Li, Yonghai [1 ]
He, Weiqing [1 ]
Wang, Yucheng [1 ]
Wang, Yiguang [1 ]
Shao, Rongguang [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Biotechnol, Minist Hlth,Key Lab Biotechnol Antibiot, Beijing 100050, Peoples R China
关键词
geldanamycin; carbamoyltransferase gene; gene inactivation; post-polyketide synthase modification; geldanamycin analogues;
D O I
10.1038/ja.2008.49
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Genetic manipulation of geldanamycin (GDM) producer Streptomyces species is a rational approach to understand biosynthesis processes and create new analogues. In this study, the carbamoyltransferase gene gdmN was inactivated by insertion of an apramycin-resistance gene aac3 (IV) into the genome of the geldanamycin-producing strain Streptomyces hygroscopicus 17997. GDM analogues produced by this mutant strain were isolated and characterized, such as new compound 4,5-dihydro-7-O-desearbamoyl-7-hydroxy- 19-O-glycylgeldanamycin. This compound could be converted to compound 4,5-dihydro-19-O-glycylgeldanamycin, another new GDM analogue, by a strain of Streptomyces hygroscopicus 17997 in which the GDM-pks was inactivated. These new compounds exhibited reductions of cytotoxicity against HepG2 cancer cells, but increases of aqueous solubility. These results suggest that a new post-polyketide synthase modification was involved in this process to produce new GDM analogues.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 36 条
[1]   Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models [J].
Banerji, U ;
Walton, M ;
Raynaud, F ;
Grimshaw, R ;
Kelland, L ;
Valenti, M ;
Judson, I ;
Workman, P .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :7023-7032
[2]   Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis [J].
Carroll, BJ ;
Moss, SJ ;
Bai, LQ ;
Kato, Y ;
Toelzer, S ;
Yu, TW ;
Floss, HG .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (16) :4176-4177
[3]   Antiviral activity and RNA polyinerase degradation following Hsp90 inhibition in a range of negative strand viruses [J].
Connor, John H. ;
McKenzie, Margie O. ;
Parks, Griffith D. ;
Lyles, Douglas S. .
VIROLOGY, 2007, 362 (01) :109-119
[4]   Reaction of geldanamycin and C17-substituted analogues with glutathione: Product identifications and pharmacological implications [J].
Cysyk, RL ;
Parker, RJ ;
Barchi, JJ ;
Steeg, PS ;
Hartman, NR ;
Strong, JA .
CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (03) :376-381
[5]   GELDANAMYCIN, A NEW ANTIBIOTIC [J].
DEBOER, C ;
MEULMAN, PA ;
WNUK, RJ ;
PETERSON, DH .
JOURNAL OF ANTIBIOTICS, 1970, 23 (09) :442-&
[6]   Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1 [J].
Egorin, MJ ;
Zuhowski, EG ;
Rosen, DM ;
Sentz, DL ;
Covey, JM ;
Eiseman, JL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 47 (04) :291-302
[7]   Rifamycin-mode of action, resistance, and biosynthesis [J].
Floss, HG ;
Yu, TW .
CHEMICAL REVIEWS, 2005, 105 (02) :621-632
[8]  
[高群杰 Gao Qunjie], 2002, [中国抗生素杂志, Chinese Journal of Antibiotics], V27, P13
[9]   Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90 [J].
Ge, Jie ;
Normant, Emmanuel ;
Porter, James R. ;
Ali, Janid A. ;
Dembski, Marlene S. ;
Gao, Yun ;
Georges, Asimina T. ;
Grenier, Louis ;
Pak, Roger H. ;
Patterson, Jon ;
Sydor, Jens R. ;
Tibbitts, Thomas T. ;
Tong, Jeffrey K. ;
Adams, Julian ;
Palombella, Vito J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (15) :4606-4615
[10]   Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer [J].
Goetz, MP ;
Toft, D ;
Reid, J ;
Ames, M ;
Stensgard, B ;
Safgren, S ;
Adjei, AA ;
Sloan, J ;
Atherton, P ;
Vasile, V ;
Salazaar, S ;
Adjei, A ;
Croghan, G ;
Erlichman, C .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1078-1087